Multichannel deep learning network for predicting survival in stage I NSCLC patients treated with SBRT.
Abstract
e20108 Background: This study aims to develop a deep learning network (DLN)-based model to predict overall survival (OS) by integrating radiomic, dosiomic, and clinical features. The objective is to identify the most influential predictors of OS in patients with non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT) within a DLN-based analytical framework. Methods: Radiomic features, dosimetric parameters, and clinical data were collected from 171 NSCLC patients treated with SBRT. Twenty-two dosiomic and clinical features were obtained for this cohort. In addition, 47 radiomic features were extracted from radiation planning CT images within the planning target volume (PTV), encompassing histogram-based, geometric, and texture features derived from gray-level co-occurrence matrix (GLCM), gray-level run-length matrix (GLRLM), and gray-level size-zone matrix (GLSZM). Univariate analysis identified 19 significant features for model development: 3 clinical (age, age-adjusted Charlson Comorbidity Index, T-stage), 4 dosiomic (gross tumor volume (GTV) size, PTV size, conformity index, mean lung dose), and 12 radiomic features. Radiomic predictors included GLSZM (gray-level non-uniformity, zone entropy, zone percentage, size-zone non-uniformity), GLRLM (run percentage, run-length non-uniformity, run entropy, low gray-level run emphasis), and GLCM (entropy, homogeneity, energy, angular second moment). OS prediction was performed using a DLN with three fully connected hidden layers (256, 128, and 64 neurons) and a dropout rate of 0.5 to reduce overfitting. Results: Across ten randomized training (70%) and testing (30%) splits, the DLN model using 12 radiomic features achieved an ROC-AUC of 0.66 ± 0.05, with a sensitivity of 0.70 ± 0.18 and a specificity of 0.62 ± 0.16 (see Table 1). Expanding the model to include dosiomic and clinical features (19 features total) substantially enhanced predictive performance, increasing sensitivity to 0.73 ± 0.13, specificity to 0.72 ± 0.16, and ROC-AUC to 0.72 ± 0.03. Conclusions: Integrating dosiomic and clinical information with radiomic features significantly strengthens deep learning–based prediction of overall survival in patients with NSCLC treated with SBRT, yielding an approximately 9% improvement in ROC-AUC over radiomics-only models. These findings underscore the clinical potential of multimodal feature integration, with ongoing multi-institutional studies underway to confirm robustness and generalizability. Performance of the DLN-based OS prediction model. Methods ROC-AUC Sensitivity Specificity F1-score Precision 12 significant radiomic features only 0.66 (±0.05) 0.70 (±0.18) 0.62 (±0.16) 0.74 (±0.12) 0.81 (±0.07) Combing radiomic (12), dosiomic (4) & clinical (3) features 0.72 ( ± 0.03) 0.73 ( ± 0.13) 0.72 ( ± 0.16) 0.78 ( ± 0.07) 0.85 ( ± 0.08)
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (6)
Kaushik Halder
SUNY Upstate Medical University, Syracuse, NY
Michael D. Mix
SUNY Upstate Medical Center, Syracuse, NY
Rihan Podder
University of Florida, Gainesville, FL
Jeffrey A. Bogart
SUNY Upstate Medical University, Syracuse, NY
Tithi Biswas
University of Florida, Gainesville, FL
Tarun Kanti Podder
SUNY Upstate Medical University, Syracuse, NY